Pulmatrix Provides a Pipeline and Business Update

Author's Avatar
Mar 04, 2021
Article's Main Image

PUR1800 Phase 1b study dosing is underway with data anticipated in Q4 2021

Pulmatrix completed FDA Type-C meeting and anticipates a Pulmazole Ph2b study start in Q1 2022

PUR3100 lead DHE (dihydroergotamine) formulation identified for pulmonary delivered acute migraine treatment

Cash runway extends beyond anticipated PUR1800 Ph1b, PUR3100 Ph1/Ph2 and Pulmazole Ph2b data milestones

PR Newswire